213 related articles for article (PubMed ID: 26844838)
1. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
[TBL] [Abstract][Full Text] [Related]
2. The role of peroxisome proliferator-activated receptor-γ in breast cancer.
Kotta-Loizou I; Giaginis C; Theocharis S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1025-44. PubMed ID: 22583414
[TBL] [Abstract][Full Text] [Related]
3. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and chemoprevention by thiazolidinediones.
Fröhlich E; Wahl R
Biomed Res Int; 2015; 2015():845340. PubMed ID: 25866814
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
[TBL] [Abstract][Full Text] [Related]
6. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Chen JY; Wang JJ; Lee HC; Chi CW; Lee CH; Hsu YC
J Chin Med Assoc; 2020 Oct; 83(10):923-930. PubMed ID: 33009242
[TBL] [Abstract][Full Text] [Related]
7. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines.
Yang YC; Tsao YP; Ho TC; Choung IP
Int J Gynecol Cancer; 2007; 17(2):418-25. PubMed ID: 17316361
[TBL] [Abstract][Full Text] [Related]
9. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.
Chu R; van Hasselt A; Vlantis AC; Ng EK; Liu SY; Fan MD; Ng SK; Chan AB; Liu Z; Li XY; Chen GG
Cancer; 2014 Jan; 120(1):142-53. PubMed ID: 24114184
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
[TBL] [Abstract][Full Text] [Related]
11. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Ohta K; Endo T; Haraguchi K; Hershman JM; Onaya T
J Clin Endocrinol Metab; 2001 May; 86(5):2170-7. PubMed ID: 11344222
[TBL] [Abstract][Full Text] [Related]
12. Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands.
Im CN
IUBMB Life; 2016 Mar; 68(3):173-7. PubMed ID: 26818439
[TBL] [Abstract][Full Text] [Related]
13. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
Mughal A; Kumar D; Vikram A
Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
[TBL] [Abstract][Full Text] [Related]
14. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.
Klopper JP; Hays WR; Sharma V; Baumbusch MA; Hershman JM; Haugen BR
Mol Cancer Ther; 2004 Aug; 3(8):1011-20. PubMed ID: 15299084
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
Park JW; Zarnegar R; Kanauchi H; Wong MG; Hyun WC; Ginzinger DG; Lobo M; Cotter P; Duh QY; Clark OH
Thyroid; 2005 Mar; 15(3):222-31. PubMed ID: 15785241
[TBL] [Abstract][Full Text] [Related]
16. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.
Xiong X; Ye Y; Fu L; Dai B; Liu J; Jia J; Tang J; Li L; Wang L; Shen J; Mei C
Invest New Drugs; 2009 Jun; 27(3):223-32. PubMed ID: 18704263
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
[TBL] [Abstract][Full Text] [Related]
19. PPAR-gamma in ulcerative colitis: a novel target for intervention.
Bertin B; Dubuquoy L; Colombel JF; Desreumaux P
Curr Drug Targets; 2013 Nov; 14(12):1501-7. PubMed ID: 23651165
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
